Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin

Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia

(2018) Tu’uhevaha J. Kaitu’u-Lino et al.   PLoS One

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment

(2017) Natalie J. Hannan et al.   Scientific Reports

Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction

(2016) Fiona C. Brownfoot et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

MicroRNA-Based Therapy of GATA2-Deficient Vascular DiseaseClinical Perspective

(2016) Dorothee Hartmann et al.   CIRCULATION

Measuring circulating placental RNAs to non-invasively assess the placental transcriptome and to predict pregnancy complications

(2016) Clare L. Whitehead et al.   PRENATAL DIAGNOSIS

Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)

(2016) Neil O'Gorman et al.   BMJ Open

Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe PreeclampsiaNovelty and Significance

(2015) Fiona C. Brownfoot et al.   HYPERTENSION

Beneficial and cautionary outcomes of resveratrol supplementation in pregnant nonhuman primates

(2014) Victoria H. J. Roberts et al.   FASEB JOURNAL

Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells

(2014) F.C. Brownfoot et al.   PLACENTA

Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin

(2014) Tu’uhevaha J. Kaitu’u-Lino et al.   Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health

Quantifying mRNA coding growth genes in the maternal circulation to detect fetal growth restriction

(2013) Clare L. Whitehead et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Redefining Preeclampsia Using Placenta-Derived Biomarkers

(2013) Anne Cathrine Staff et al.   HYPERTENSION

Placental Specific mRNA in the Maternal Circulation Are Globally Dysregulated in Pregnancies Complicated by Fetal Growth Restriction

(2013) Clare L. Whitehead et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Optimising sample collection for placental research

(2013) G.J. Burton et al.   PLACENTA

ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder

(2012) Elena Milanesi et al.   BMC Psychiatry

Cell Free Expression of hif1α and p21 in Maternal Peripheral Blood as a Marker for Preeclampsia and Fetal Growth Restriction

(2012) Osnat Ashur-Fabian et al.   PLoS One

15 million preterm births annually: what has changed this year?

(2012) Mary V Kinney et al.   Reproductive Health

Measurement of mRNA Transcripts of Very High Placental Expression in Maternal Blood as Biomarkers of Preeclampsia

(2011) Premila Paiva et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Critical Review of Early-Onset and Late-Onset Preeclampsia

(2011) Dahlia Raymond et al.   OBSTETRICAL & GYNECOLOGICAL SURVEY

Evaluation of 7 Serum Biomarkers and Uterine Artery Doppler Ultrasound for First-Trimester Prediction of Preeclampsia: A Systematic Review

(2011) Sylwia Kuc et al.   OBSTETRICAL & GYNECOLOGICAL SURVEY

Abnormal Placentation, Angiogenic Factors, and the Pathogenesis of Preeclampsia

(2010) Michelle Silasi et al.   OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA

Preeclampsia: The Role of Angiogenic Factors in Its Pathogenesis

(2009) Alice Wang et al.   PHYSIOLOGY

The Global Impact of Pre-eclampsia and Eclampsia

(2009) Lelia Duley   SEMINARS IN PERINATOLOGY

miR-126 Regulates Angiogenic Signaling and Vascular Integrity

(2008) Jason E. Fish et al.   DEVELOPMENTAL CELL